Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 210

Similar articles for PubMed (Select 22466322)

1.

Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children.

Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, Belshe RB.

Pediatr Infect Dis J. 2012 Jul;31(7):745-51. doi: 10.1097/INF.0b013e31825687b0.

PMID:
22466322
2.

A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.

Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J.

Vaccine. 2011 Nov 21;29(50):9391-7. doi: 10.1016/j.vaccine.2011.09.109. Epub 2011 Oct 6.

PMID:
21983154
3.

Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study*.

Sheldon EA, Jeanfreau R, Sliman JA, Charenkavanich S, Rousculp MD, Dubovsky F, Mallory RM.

Influenza Other Respir Viruses. 2013 Nov;7(6):1142-50. doi: 10.1111/irv.12027. Epub 2012 Oct 14.

4.

Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.

Toback SL, Levin MJ, Block SL, Belshe RB, Ambrose CS, Falloon J.

Expert Rev Vaccines. 2012 Nov;11(11):1293-303. doi: 10.1586/erv.12.108. Epub 2012 Nov 14. Review.

PMID:
23151111
5.

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.

King JC Jr, Fast PE, Zangwill KM, Weinberg GA, Wolff M, Yan L, Newman F, Belshe RB, Kovacs A, Deville JG, Jelonek M; HIV Influenza Study Group.

Pediatr Infect Dis J. 2001 Dec;20(12):1124-31.

PMID:
11740317
6.

Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.

Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.

Pediatrics. 2006 Sep;118(3):e579-85.

PMID:
16950949
7.

Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects.

Block SL, Reisinger KS, Hultquist M, Walker RE; CAIV-T Study Group.

Antimicrob Agents Chemother. 2007 Nov;51(11):4001-8. Epub 2007 Aug 27.

8.

Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.

Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE.

Vaccine. 2008 Sep 8;26(38):4940-6. doi: 10.1016/j.vaccine.2008.07.013. Epub 2008 Jul 26.

PMID:
18662737
9.

Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.

Bracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino G, Small MG, Gruber WC, Forrest BD; D153-P504 LAIV Study Group.

Pediatr Infect Dis J. 2009 May;28(5):365-71. doi: 10.1097/INF.0b013e31819219b8.

PMID:
19395948
10.

Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities.

Nolan T, Lee MS, Cordova JM, Cho I, Walker RE, August MJ, Larson S, Coelingh KL, Mendelman PM.

Vaccine. 2003 Mar 7;21(11-12):1224-31.

PMID:
12559802
11.

Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.

Mallory RM, Yi T, Ambrose CS.

Vaccine. 2011 Jun 10;29(26):4322-7. doi: 10.1016/j.vaccine.2011.04.022. Epub 2011 Apr 20.

PMID:
21513761
12.

Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.

Carr S, Allison KJ, Van De Velde LA, Zhang K, English EY, Iverson A, Daw NC, Howard SC, Navid F, Rodriguez-Galindo C, Yang J, Adderson EE, McCullers JA, Flynn PM.

J Infect Dis. 2011 Nov 15;204(10):1475-82. doi: 10.1093/infdis/jir561. Epub 2011 Sep 23.

13.

Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?

Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.

Pediatrics. 2006 Sep;118(3):e570-8.

PMID:
16950948
14.

Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.

Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts M, Kozinetz C, Hessel C, Glezen WP.

Pediatrics. 2005 Sep;116(3):e397-407.

15.

Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials.

Mallory RM, Malkin E, Ambrose CS, Bellamy T, Shi L, Yi T, Jones T, Kemble G, Dubovsky F.

PLoS One. 2010 Oct 29;5(10):e13755. doi: 10.1371/journal.pone.0013755.

16.

Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.

Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X.

Vaccine. 2010 Feb 25;28(9):2149-56. doi: 10.1016/j.vaccine.2009.11.068. Epub 2009 Dec 8.

PMID:
20003926
17.

A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.

Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.

J Infect Dis. 2013 Jun 15;207(12):1878-87. doi: 10.1093/infdis/jit091. Epub 2013 Mar 7.

18.

Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers.

Heldens J, Hulskotte E, Voeten T, Breedveld B, Verweij P, van Duijnhoven W, Rudenko L, van Damme P, van den Bosch H.

Vaccine. 2014 Sep 3;32(39):5118-24. doi: 10.1016/j.vaccine.2014.05.030. Epub 2014 May 23.

PMID:
24858566
19.

Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial.

Davidson LE, Fiorino AM, Snydman DR, Hibberd PL.

Eur J Clin Nutr. 2011 Apr;65(4):501-7. doi: 10.1038/ejcn.2010.289. Epub 2011 Feb 2.

20.

Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer.

Halasa N, Englund JA, Nachman S, Weinberg GA, Huber VC, Allison K, Dubovsky F, Yi T, McCullers JA, Flynn PM.

Vaccine. 2011 May 31;29(24):4110-5. doi: 10.1016/j.vaccine.2011.03.097. Epub 2011 Apr 13.

PMID:
21496468
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk